The Wegovy 2.4mg dose chart: what the schedule looks like and why it matters

What does the Wegovy titration chart actually show?

The chart maps a stepped journey rather than a single destination. You begin at 0.25mg weekly — a dose low enough that most people feel little beyond mild settling-in effects. After four weeks you move to 0.5mg, then 1.0mg, then 1.7mg, and finally 2.4mg. That last step typically arrives around week seventeen or eighteen, assuming each stage went smoothly. The full picture is set out in the Wegovy dose chart guide, which walks through each rung in detail.

A question our prescribers hear most weeks is whether the chart is a rigid timetable or more of a rough guide. The honest answer is both. The four-week intervals are the licensed standard, but your prescriber can hold you at a lower dose longer if side effects are troublesome, or review whether a step is appropriate at all. What the chart is not is a self-service menu. Each move up requires clinical sign-off, which is why repeat prescriptions at nume involve a fresh review before anything is dispensed.

It is also worth knowing that 2.4mg became the headline figure partly because it was the dose used in the pivotal clinical trials, it is where the headline efficacy data lives. The earlier doses are titration steps, not therapeutic targets in their own right.

Why does the schedule stop (or not stop) at 2.4mg?

For most adults on Wegovy, 2.4mg has been the ceiling. That changed in January 2026, when the MHRA approved a 7.2mg maintenance dose, initially delivered as three 2.4mg pens per week, and then in April 2026 as a dedicated single-dose 7.2mg pen. So the chart now has a potential extension, though the higher dose is licensed specifically for adults with a BMI of 30 or above, and whether it is appropriate is a clinical decision made with your prescriber.

If you are already on 2.4mg and wondering where that leaves you, the short answer is that most people stay at this level and continue to see results as long as treatment continues alongside lifestyle changes. Our Wegovy doses chart covers every licensed dose and titration step, including the newer 7.2mg pen, in more detail. For the specific click-count reference that some patients use to check their pen is delivering correctly, our guide to the Wegovy 2.4 clicks chart has that information.

One practical note: the NICE appraisal of semaglutide for weight management (NICE TA875) recommends stopping treatment if weight loss is less than 5% after six months at the maintenance dose. Your prescriber will review this at that point. It is not a failure; it is a clinical checkpoint.

What are the side effects that make the slow chart necessary?

Semaglutide works partly by slowing how quickly your stomach empties, and at higher doses that effect is more pronounced. Starting low and moving gradually gives the gut time to adapt. The side effects most people notice are gastrointestinal: nausea, loose stools, constipation, reflux, or some combination. They tend to peak in the first few days after a dose increase and ease over the following week or two for most people. Not everyone experiences them, and severity varies considerably.

The NHS medicines page for semaglutide has a clear list of what to expect and which symptoms warrant contacting a doctor promptly. One worth flagging here: severe, persistent stomach pain that radiates to the back can be a sign of pancreatitis, which requires urgent medical attention. It is uncommon, but the MHRA highlighted it in a Drug Safety Update for GLP-1 medicines, report any suspected reactions via the Yellow Card scheme.

Sticking to the chart rather than rushing it is one of the most practical things you can do to keep side effects manageable. Skipping steps is not something to do without a prescriber's guidance; jumping from 1.0mg to 2.4mg in one go would almost certainly make the first week unpleasant. The chart exists for good reason.

Does reaching 2.4mg mean the process is over?

Not quite. Reaching the maintenance dose is a milestone, not a finish line. Weight loss at 2.4mg continues over months, and clinical trials ran to 68 weeks precisely because meaningful change takes time. The STEP 1 trial, published in the New England Journal of Medicine, reported roughly 15% average weight reduction at that endpoint, achieved by people who had been on the full maintenance dose for an extended period, not just a few weeks.

For people thinking about cost alongside the clinical picture, our treatment overview puts the options in context. And if you are still weighing up whether Wegovy is the right medicine for your situation, the Wegovy treatment page covers eligibility, how it compares with other licensed options, and what a consultation with our prescribers involves.

Speak to our prescribers if you have questions about where you are on the titration schedule, whether 2.4mg is working, or what the next clinical step looks like, that conversation starts with a free consultation.